3-(3'-t-Butylphenyl)-propionsaeure | 53987-61-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(3'-t-Butylphenyl)-propionsaeure
• 英文别名: 3-(3-Tert-butylphenyl)propanoic acid
• CAS: 53987-61-4
• 化学式: C₁₃H₁₈O₂
• 分子量: 206.285
• InChiKey: ICKJGLNUALQTFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(3'-t-Butylphenyl)-propionsaeure 在 氢氟酸 作用下， 生成 5-叔丁基-1-茚满酮
  参考文献：
  名称：

  Brouwers, Louvain Medical, 1974, vol. 93, # 4, p. 189 - 194

  摘要：

  DOI：

文献信息

• INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
  申请人：Roth Juergen Gerald

  公开号：US20070004757A1

  公开（公告）日：2007-01-04

  The present invention relates to indolinone derivatives, substituted in the 6-position, of the formula in which R 1 to R 6 and X are as defined in Claim 1 , to their tautomers, enantiomers, diastereomers, to their mixtures and to their salts, in particular their physiologically acceptable salts, which have useful pharmacological properties, in particular in inhibiting action on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, to medicaments comprising these compounds, to their use and to processes for their preparation.

  本发明涉及6-位取代的吲哚酮衍生物，其化学式为其中R1至R6和X如权利要求1所定义，以及它们的互变异构体、对映异构体、非对映异构体、混合物和盐，特别是其生理上可接受的盐，具有有用的药理学性质，特别是在抑制各种受体酪氨酸激酶和内皮细胞以及各种肿瘤细胞的增殖方面，以及包含这些化合物的药物、它们的用途和制备方法。
• MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
  申请人：PARK John Edward

  公开号：US20100204211A1

  公开（公告）日：2010-08-12

  The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R 1 to R 5 and X are defined as in claim 1 , the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

  本发明涉及使用通式中6位取代的吲哚酮，其中R1至R5和X如权利要求1所定义，其异构体和盐，特别是其生理上可接受的盐，作为预防或治疗特定纤维化疾病的药物。
• GUANIDINOBENZOIC ACID COMPOUND
  申请人：Fujiyasu Jiro

  公开号：US20140378459A1

  公开（公告）日：2014-12-25

  [Problem] Provided is a compound which is useful as an agent for preventing and/or treating renal diseases. [Means for Solution] The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.

  [问题] 提供了一种化合物，可用作预防和/或治疗肾脏疾病的药剂。[解决方案] 现有发明人对具有胰蛋白酶抑制作用的化合物进行了广泛的研究，结果发现一种鸟氨酸苯甲酸化合物具有胰蛋白酶抑制作用，从而完成了本发明。本发明的鸟氨酸苯甲酸化合物可用作代替低蛋白饮食疗法的药剂，以及预防和/或治疗胰蛋白酶相关疾病（例如，胰腺炎，胃食管反流病，肝性脑病，流感等）的药剂。
• INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
  申请人：ROTH Gerald Juergen

  公开号：US20090197876A1

  公开（公告）日：2009-08-06

  The present invention relates to indolinone derivatives, substituted in the 6-position, of the formula in which R 1 to R 6 and X are as defined in Claim 1 , to their tautomers, enantiomers, diastereomers, to their mixtures and to their salts, in particular their physiologically acceptable salts, which have useful pharmacological properties, in particular in inhibiting action on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, to medicaments comprising these compounds, to their use and to processes for their preparation.

  本发明涉及6-位取代的吲哚酮衍生物，其化学式如下：其中R1至R6和X如权利要求1所定义，以及它们的互变异构体、对映异构体、非对映异构体、它们的混合物和它们的盐，特别是它们的生理上可接受的盐，具有有用的药理特性，特别是在抑制各种受体酪氨酸激酶和内皮细胞以及各种肿瘤细胞增殖方面，以及包含这些化合物的药物、它们的使用和它们的制备方法。
• Polypropylene-talc composite with reduced malodour
  申请人：Borealis AG

  公开号：EP2530116B1

  公开（公告）日：2017-10-11